Preladenant (SCH 420814) was a drug that was developed by
Schering-Plough which acted as a potent and selective
antagonist at the
adenosineA2A receptor. It was being researched as a potential treatment for
Parkinson's disease.[1] Positive results were reported in Phase II
clinical trials in humans,[2] but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.[3]
References
^Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, et al. (July 2009). "Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression". The Journal of Pharmacology and Experimental Therapeutics. 330 (1): 294–303.
doi:
10.1124/jpet.108.149617.
PMID19332567.
S2CID22033475.
^Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, et al. (March 2011). "Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial". The Lancet. Neurology. 10 (3): 221–229.
doi:
10.1016/S1474-4422(11)70012-6.
PMID21315654.
S2CID39226234.